Dr. Diasio is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511- Is this information wrong?
Summary
- My basic research interest has focused mainly on the area of cancer pharmacogenetics/pharmacogenomics. My contributions have included the initial clinical and pharmacologic characterization of the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency. More recently research in my lab has helped to characterize the molecular basis for DPD deficiency and to develop genomic tests to predict DPD deficiency.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1973 - 1976
University of RochesterResidency, Internal Medicine, 1971 - 1973
Yale School of MedicineClass of 1971
Certifications & Licensure
AL State Medical License 1984 - 2018
VA State Medical License 1976 - 2012
Awards, Honors, & Recognition
- Elected Member Association of American Physicians, 2002
- American Society for Clinical Investigation 1998
- Fellow American Association for Advancement of Science
Publications & Presentations
PubMed
- Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.Le Teuff, G., Cozic, N., Boyer, J., Boige, V., Diasio, R., Taieb, J., Meulendijks, D., Palles, C., Schwab, M., Deenen, M., Largiadèr, C., Marinaki, A., Jennings, B., W...> ;British Journal of Cancer. 2024 Mar 1
- 7 citationsTesting: Time to Put Patient Safety First.Sharyn D Baker, Susan E Bates, Gabriel A Brooks, William L Dahut, Robert B Diasio, Wafik S El-Deiry, William E Evans, William D Figg, Dan L Hertz, J Kevin Hicks, Sunee...> ;Journal of Clinical Oncology. 2023 May 20
- Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine.Melissa Lumish, Jennifer Thackray, Richard Kinh Gian Do, Kelly E Caudle, Ursula Amstutz, Matthias Schwab, Robert B Diasio, William R Jarnagin, Andrea Cercek> ;JCO Precision Oncology. 2023 Feb 1
- Join now to see all
Press Mentions
Her Cancer Surgery Was a Success. Then a Genetic Condition Let a Chemo Drug Ravage Her BodyNovember 13th, 2019
Mayo Clinic Cancer Center Renews Research Funding from the National Cancer InstituteSeptember 11th, 2019
Mayo Clinic Cancer Center Renews National Cancer Institute Research FundingSeptember 9th, 2019- Join now to see all
Grant Support
- Mayo Clinic Cancer CenterNational Cancer Institute2014–Present
- Mayo Comprehensive Cancer Center GrantNational Cancer Institute2006–2012
- SupplementNational Cancer Institute2009–2010
- Screening For Decreased 5-Fluorouracil CatabolismNational Cancer Institute2006–2010
- Dihydropyrimidine Dehydrogenase (DPD) Deficiency In Population StudiesNational Center For Research Resources2005–2007
- Genetic Polymorphism Of Dihydropyrimidine DehydrogenaseNational Cancer Institute1994–2006
- Molecular Approach In Predicting 5-Fluorouracil EfficacyNational Cancer Institute2005
- Molecular Approach In Predicting 5-Fluorouracil EfficacyNational Cancer Institute2002–2005
- Genetic Polymorphism Of Dpd: Ident. Of DPD DeficiencyNational Center For Research Resources2004
- Molecular Approach In Predicting 5 Fluorouracil EfficacyNational Cancer Institute2001
- Pharmacokinetic &Metabolic Evaluation Of 5FU In The Presence Of Oral 776c85National Center For Research Resources1998–2000
- National Cancer Institute Initial Review GroupNational Cancer Institute1996–1999
- Oral BCX 34 In T Cell MaliganciesNational Center For Research Resources1998
- Chronic Oral 5-FU In Combination With 776c85National Center For Research Resources1996–1997
- BCX 34 In T Cell MaliganciesNational Center For Research Resources1996–1997
- Cancer And Leukemia Group BNational Cancer Institute1995–1997
- Oral Sorivudine, Bvu &Dpd Activity In Peripheral Blood Mononuclear CellsNational Center For Research Resources1996
- Anti B4 Blocked Ricin In B Lineage All/High Dose Cytarabin In NON B Lineage AllNational Center For Research Resources1996
- Clinical Pharmacology Of IVX-E-59 In HIV Using (2-14c)Azt-P(2'3-3h)DdiNational Center For Research Resources1995
- DDTC As A Protective Agent Against Cisplatin ToxicitiesNational Center For Research Resources1992–1995
- 5-FU And Radiolabled Zidovudine (3h-Azt) In Colorectal CancerNational Center For Research Resources1992–1995
- Examination Of The Metabolism Of 5-Fluorouracil In ManNational Center For Research Resources1990–1995
- Biochemical Pharmacologic Studies Of Anticancer And Antiviral DrugsNational Center For Research Resources1990–1995
- Mechanism Of Toxicity Of Fluorocytosine And FluorouracilNational Cancer Institute1987–1994
- Continuous IV Infusion Of FUDR In Patients With Metastatic CarcinomaNational Center For Research Resources1990
- Mechanism Of Toxicity Of Fluorocytosine And FluorouracilNational Cancer Institute1985–1987
Professional Memberships
- Member
- American Society for Clinical Pharmacology and TherapeuticsMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
